Last reviewed · How we verify
GnRh agonist +1500E hCG
A GnRH agonist combined with hCG that stimulates the pituitary-gonadal axis to increase gonadotropin secretion and sex hormone production.
A GnRH agonist combined with hCG that stimulates the pituitary-gonadal axis to increase gonadotropin secretion and sex hormone production. Used for Ovulation induction in assisted reproductive technology (ART), Male infertility due to hypogonadism.
At a glance
| Generic name | GnRh agonist +1500E hCG |
|---|---|
| Sponsor | AZ Jan Palfijn Gent |
| Drug class | GnRH agonist with hCG supplementation |
| Target | GnRH receptor; LH receptor (via hCG) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
GnRH agonists initially stimulate the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then act on the gonads. The addition of exogenous hCG (human chorionic gonadotropin) provides supplemental LH-like activity to further stimulate testosterone or estrogen production. This combination is typically used in fertility treatment to support ovulation induction or spermatogenesis.
Approved indications
- Ovulation induction in assisted reproductive technology (ART)
- Male infertility due to hypogonadism
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRh agonist +1500E hCG CI brief — competitive landscape report
- GnRh agonist +1500E hCG updates RSS · CI watch RSS
- AZ Jan Palfijn Gent portfolio CI